The Monoclonal Antibodies Unit provides CNIO and other national and international research groups with the capability to generate “à la carte” monoclonal antibodies (mAbs) that are used as research tools to isolate, identify, and characterise new pathways relevant to cancer diagnosis, prevention, and treatment.
Our mAbs are useful tools to understand cancer biology and to diagnose neoplastic diseases, since they allow the identification of molecular markers that are selectively expressed by specific tumour subtypes.
We are particularly specialised in the production and validation of mAbs for immunohistochemistry (IHC), a technique that allows the localisation and study of proteins in tissue sections. This type of reagent allows for a more accurate diagnosis, resulting in a better classification of cancer and the selection of the most adequate cancer treatment.
The Unit also offers mAb characterisation and validation, medium-scale mAb production, as well as a service of Mycoplasma testing for the cell culture facility.